PT - JOURNAL ARTICLE AU - Pelissari, Daniele M AU - Bartholomay, Patricia AU - Johansen, Fernanda Dockhorn Costa AU - Diaz-Quijano, Fredi A TI - Impact of the COVID-19 pandemic on tuberculosis notification in Brazil AID - 10.1101/2022.09.05.22279616 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.05.22279616 4099 - http://medrxiv.org/content/early/2022/09/09/2022.09.05.22279616.short 4100 - http://medrxiv.org/content/early/2022/09/09/2022.09.05.22279616.full AB - Background The COVID-19 pandemic notably impacted tuberculosis notification and detection in Brazil. We estimated the number of unnotified tuberculosis cases by group population over the first two years (2020-2021) of the pandemic.Methods We extracted tuberculosis case notifications from routine national surveillance records and population from Ministry of Health. We estimated trends for case notification during pre-pandemic period (2015–2019), stratified by sex, age group, and State with a mixed-effects model. We calculated the unnotified cases during 2020-2021 as the difference between expected, and reported values.Results We estimated 11647 (95% uncertain interval [95%UI]: 829,22466) unnotified cases for 2020; and, 6170 (95%UI: -4629,16968) for 2021; amounting 17817 unnotified cases over the two years. Of the estimated expected tuberculosis cases in 2020 and 2021, 11.2% were not notified. Across sex and age, men aged 30-59 years had the highest number of unnotified cases, and men aged 0-14 years had the highest proportion of unnotified cases. Case underreporting was significant for 13 (of the 27 States) in 2020, and for four in 2021.Conclusions Tuberculosis cases notification decreased substantially during the COVID-19 pandemic in Brazil. Our analysis helped identify the most affected populations to plan strategies to mitigate the effects of the pandemic on tuberculosis control.Evidence before this study A systematic review was conducted to retrieve studies that aimed the impact of the COVID-19 pandemic on tuberculosis detection in PubMed with the following terms: “(TB or tuberculosis) and (incidence or case or notification or burden) and (COVID-19 or pandemic)” from January 2020 to May 2022, returning 189 records. Out of these studies, we analyzed 17 that reported a decrease in tuberculosis notification during the pandemic years, and most of them with data only from the first year of the pandemic. Two studies were carried out with Brazilian data. One of them focused on the number of tuberculosis consultations at the benning of the pandemic, and the other was a government bulletin describing tuberculosis notification. As far as we know, no study has examined the tuberculosis case notification in Brazil during the two years of the pandemic, by group population. Furthermore, none of them had predicted the expected cases considering local trends in both the incidence of tuberculosis and its main determinants.Added value of this study Using tuberculosis case reports from routine national surveillance registries, we estimated case notification trends during the pre-pandemic period (2015–2019), stratified by sex, age group, and State and calculated the unnotified cases during 2020-2021. Brazil lost 11647 (95% uncertain interval [95%UI]: 829,22466) tuberculosis cases in 2020; and, 6170 (95%UI: - 4629,16968) in 2021, which represents 11.2% of underreporting in both years. Across sex and age, men aged 30 to 59 years had the highest number of unnotified cases, and men aged 0 to 14 years had the highest proportion of unnotified cases. Case underreporting was significant for 13 (of the 27 States) in 2020, and for four in 2021.Implications of all the available evidence The COVID-19 pandemic had a catastrophic effect in tuberculosis notification in Brazil during 2020 and 2021. This resulted in a setback in progress made over decades in tuberculosis control, and highlight the threat posed by tuberculosis transmission. Several lessons learned from response to COVID-19 provide an opportunity to improve the notification of respiratory diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFADQ is beneficiary of a fellowship for research productivity from the National Council for Scientific and Technological Development CNPq: 312656/2019 0. This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brazil CAPES tese award (Edital N 3/2021).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are openly accessible and available through the sources listed in the manuscript.